Skip to main content
Premium Trial:

Request an Annual Quote

Bruker and Charles River Ink Deal to Link MALDI Biotyper and Accugenix Database

Premium

Bruker and Charles River said this week they have agreed to a partnership deal under which they will sell Bruker's MALDI Biotyper system packaged with access to Charles River's cGMP-compliant Accugenix microbial database.

Called the Axcess System, the new product is aimed at environmental monitoring applications and will allow Biotyper customers to "have access to the most current and validated database for identifications, saving time and costs associated with validating library releases," the companies said.

Charles River will also provide sequence-based identifications of organisms that are not identified by the Biotyper, reducing customers' needs for secondary systems. The product is intended for use in markets including the pharmaceutical, biopharmaceutical, personal care, and other manufacturing industries, the companies said.

"With Charles River products in virtually every pharmaceutical microbiology laboratory, we are looking forward to working with Charles River to expand our efforts to make the MALDI Biotyper the new standard in microbial identification for industrial microbiology,” Gary Kruppa, Bruker's vice president of business development, said in a statement.

Launched by Bruker in 2006, the MALDI Biotyper identifies bacteria by matching their protein fingerprints against fingerprints contained in Bruker's proprietary database. The company has installed more than 800 of the devices worldwide.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.